Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Shah, Shilpan ^a   Loghavi, Sanam ^a   Garcia Manero, Guillermo ^a   Khoury, Joseph D ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Chronic myelomonocytic leukemia; FIP1L1 PDGRFA; Imatinib mesylate

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CYTARABINE; DNA METHYLTRANSFERASE INHIBITOR; HYDROXYUREA; IDARUBUCIN; IMATINIB; SGI 110; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FIP1L1-PDGFRA FUSION PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOGENETICS; DRUG DOSE ESCALATION; FIP1L1 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; HUMAN TISSUE; KARYOTYPE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOID HYPERPLASIA; MALE; MIDDLE AGED; MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISEASE; MOLECULAR DIAGNOSIS; MULTICENTER STUDY (TOPIC); PDGFRA GENE; REFRACTORY ACUTE MYELOID LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; TREATMENT OUTCOME; TRISOMY 8; EOSINOPHILIA; GENETICS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; METABOLISM; MUTATION; PATHOLOGY;

BENZAMIDES; EOSINOPHILIA; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS, FUSION; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TREATMENT OUTCOME;

EID: 84899128502     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-26     Document Type: Article

References (18)

1. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Pardanani A, Ketterling RP, Li CY, Patnaik MM, Wolanskyj AP, Elliott MA, Camoriano JK, Butterfield JH, Dewald GW, Tefferi A, Leuk Res 2006 30 8 965 70 10.1016/j.leukres.2005.11.011 16406016
2. The results of imatinib therapy for patients with primary eosinophilic disorders. Helbig G, Stella-Holowiecka B, Grosicki S, Bober G, Krawczyk M, Wojnar J, Reiter A, Hochhaus A, Holowiecki J, Eur J Haematol 2006 76 6 535 6 10.1111/j.1600-0609.2006.00652.x 16608506
3. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Helbig G, Stella-Hołowiecka B, Majewski M, Całbecka M, Gajkowska J, Klimkiewicz R, Moskwa A, Grzegorczyk J, Lewandowska M, Hołowiecki J, Br J Haematol 2008 141 2 200 4 10.1111/j.1365-2141.2008. 07033.x 18307562
4. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S, Blood 2013 122 19 3387 8 10.1182/blood-2013-07-516500 24203930
5. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NC, Hehlmann R, Hochhaus A, Reiter A, Br J Haematol 2008 143 5 707 15 10.1111/j.1365-2141.2008.07294.x 18950453
6. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JD, Am J Hematol 2013 88 12 1055 61 10.1002/ajh.23567 23940084
7. Class III receptor tyrosine kinases: role in leukaemogenesis. Reilly JT, Br J Haematol 2002 116 4 744 57 10.1046/j.0007-1048.2001.03294.x 11886377
8. The human PDGF receptor alpha-subunit gene maps to chromosome 4 in close proximity to c-kit. Gronwald RG, Adler DA, Kelly JD, Disteche CM, Bowen-Pope DF, Hum Genet 1990 85 3 383 5 1697560
9. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG, N Engl J Med 2003 348 13 1201 14 10.1056/NEJMoa025217 12660384
10. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A, Blood 2004 104 10 3038 45 10.1182/blood-2004-03-0787 15284118
11. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Pardanani A, Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A, Blood 2003 102 9 3093 6 10.1182/blood-2003-05-1627 12842979
12. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Gotlib J, Acta Haematol 2005 114 1 7 25 10.1159/000085559 15995322
13. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM, N Engl J Med 2002 347 7 481 7 10.1056/NEJMoa020150 12181402
14. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, Gardembas M, Goldman JM, Grand F, Hughes G, Huguet F, Lavender L, McArthur GA, Mahon FX, Massimini G, Melo J, Rousselot P, Russell-Jones RJ, Seymour JF, Smith G, Stark A, Waghorn K, Nikolova Z, Apperley JF, Blood 2007 109 1 61 4 10.1182/blood-2006-05-024828 16960151
15. Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib. Drechsler M, Hildebrandt B, Kündgen A, Germing U, Royer-Pokora B, Ann Hematol 2007 86 5 353 4 10.1007/s00277-006-0247-5 17211520
16. A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome. La Starza R, Rosati R, Roti G, Gorello P, Bardi A, Crescenzi B, Pierini V, Calabrese O, Baens M, Folens C, Cools J, Marynen P, Martelli MF, Mecucci C, Cuneo A, Leukemia 2007 21 4 830 3 17301821
17. Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia. Zota V, Miron PM, Woda BA, Raza A, Wang SA, J Clin Oncol 2008 26 12 2040 1 10.1200/JCO.2007.15.3841 18421057
18. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Leukemia 2007 21 6 1183 8 10.1038/sj.leu.2404662 17377585